• Tetrodotoxin produced analgesia for full thickness burn wound pain.
Introduction
In 2013 alone, an estimated 450,000 burn incidents were reported according to the American Burn Association (http:// burninjuryguide.com/burn-statistics/). The severity of burn wounds varies, but pain is universal and is especially an issue in 2nd and 3rd degree burns. Burn wounds produce excessive pain during treatment, which can have a profound impact on the quality of life and rehabilitation. Our research is focused on improving pain care for severely burned military service members. Current management of severe burn pain, both in military and civilian populations, is primarily through the systemic delivery of opioids, causing unintended and adverse side effects [2, 5] . These include cardiac and respiratory depression, and decrease in motor and cognition function amongst others. In addition, extended opioid use is often necessary for the most severely burned patients, and can lead to tolerance, opioid-induced hyperalgesia, and dependence [1, 17] .
Tetrodotoxin (TTX), a selective voltage-gated sodium (Na + ) channel blocker, was originally identified as a neurotoxin in marine animals, where it is utilized as a defense against predators [14] . TTX has been shown to have analgesic effects in a multitude of pain models including, the hot-plate test (acute pain model), formalin test (persistent pain model), and spinal nerve ligation and sciatic nerve chronic constriction tests (neuropathic pain models) [16, 18, 21] . Also, TTX is currently in clinical trials as an analgesic. A recently completed phase 3 clinical trial for cancer-related pain, phase 2 clinical trial for chemotherapy-induced neuropathic pain and a number of other trials have established overall safety for humans [10, 11] . The antinociceptive effects of TTX are thought to be due to stabilization of neuronal membranes via inhibition of Na + ion flux required for initiation and conduction of nociceptive impulses. To date, the analgesic effect of TTX has not been tested for burn pain, although TTX is known to block Na + channels expressed on nociceptive fibers [23] , including sodium channel Na v 1.7, which has been shown to be essential in lowering the heat pain threshold after burn injury [24] .
In this study we have tested the antinociceptive effects of TTX in a rat hindpaw full thickness thermal injury pain model, which recapitulates many aspects of human burn pain [9] . We show that TTX significantly reduces thermal hyperalgesia within 2 h following administration and that this effect does not produce hyperalgesia when administered daily over several days, as is the case for morphine [15] . Also, TTX did not significantly affect motor coordination. A burn pain indication for TTX would fulfill an unmet need for an analgesic that can either replace, or reduce quantities of administered opioid analgesics. These results suggest that TTX could be developed as an effective, rapidly acting analgesic for battlefield burn injuries.
Material and methods

Rat full thickness thermal injury (FTTI) model
A total of 27 adult (250-400 g) intact male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA, USA) were used in these experiments. Rats were pair housed in a 12:12 h light:dark cycle with ad libitum access to food and water. All studies were approved by the U.S. Army Institute of Surgical Research Institutional Animal Care and Use Committee and conformed to the ILAR Guide for the Care and Use of Laboratory Animals and all applicable Federal, DoD, state, and local regulations. The animal facility is fully accredited by AAALAC, Intl.
Rats were subjected to a hindpaw full thickness thermal injury pain protocol that was developed by our research team [9] . Briefly, animals were anesthetized with isoflurane and injury was induced using a temperature-controlled super soldering station equipped with a slanted soldering tip (RX-80HRT-5.4D; Goot, Hiroshima, Japan). The soldering tip was heated to 100 • C and placed on the right hindpaw for 30 s, producing an approximately 0.25 m 2 thermal injury on the ventral surface of the hindpaw. This procedure resulted in a partial-thickness thermal injury, which progressed to full thickness over the course of 24-48 h. To prevent infection, silver sulfadiazine (1%) ointment was applied once to the injury. the day of administration The lyophilized product was reconstituted with sterile water and further diluted with normal saline to a final concentration of 8 g/ml. Unused portions were stored at 4-8 • C for up to 48 h. Vehicle control preparations were made using identical lyophilized carrier brought to the same final volume. Morphine (1 mg/ml) was purchased from Hospira Inc., TTX (8 g/kg), morphine (5 mg/kg) or vehicle was administered subcutaneously (SC) in the flank region at the times indicated in Fig. 1 , for systemic treatment.
Drug treatments
Behavioral testing
Nine rats were treated per group (control/morphine/TTX). All behavioral tests were performed by observers who were did not administer the treatments and who were blinded to treatment allocation. To obtain nociceptive thresholds to an acute noxious stimulus (hyperalgesia), paw withdrawal latencies (PWL) to a radiant beam of light were determined utilizing a Paw Thermal Stimulator (Univ. California, San Diego, CA, USA) as previously described [13] . Rats were acclimated to the testing apparatuses and a baseline measurement was taken prior to thermal injury. Drugs were administered daily for 5 days beginning 72 h post-thermal injury. PWLs were recorded 60 min and 120 min after each drug administration ( Fig. 1) . A pretreatment baseline was also taken each day immediately prior to drug administration. Nociceptive responses to a non-noxious mechanical stimulus (mechanical allodynia) were determined using a Dynamic Plantar Aesthesiometer (Ugo Basile; Collegeville, PA, USA) with automatic detection capability. For this test, the same rats used for thermal testing were placed on a mesh grid immediately following the thermal test and after a 10 min acclimation period, a blunt probe was applied to the plantar surface approximately 5 mm proximal to the thermal injury. Grams of force applied to elicit withdrawal of the hindpaw were recorded daily for 5 days beginning 72 h post-thermal injury. In addition both thermal hyperalgesia and mechanical allodynia measurements were taken on days 10, 14, and 16 post thermal injury.
Data analysis
All data were analyzed using GraphPad Prism software version 5 (GraphPad, San Diego, CA, USA). Pain behavior data are expressed as mean ± standard error of the mean (SEM) of either PWL or Force to Withdrawal. Significant outliers were identified for exclusion with the Grubbs' test (GraphPad Quick Calcs Online, the extreme studentized deviate method; [Z = (mean-value)/standard deviation], where the value is excluded if Z > 2.21) to detect outliers over 2 standard deviations from the mean. All data were analyzed by two-way ANOVA and Tukey's post hoc tests to correct for multiple comparisons. The statistical significance was tested at p < 0.05. Figs. 2 and 3 , respectively, at the indicated days post-thermal injury. The same rats were tested as above, such that days 10, 14 and 16 correspond to 3,7, and 9 days after the 5th drug treatment. There was no statistically significant difference comparing each treatment to vehicle controls at a given time point.
Results
We used the FTTI burn pain model to determine the effect of TTX administration, along with morphine as a positive control, on postburn injury pain behaviors in response to both a noxious and nonnoxious stimulus, to determine efficacy for thermal hyperalgesia and mechanical allodynia, respectively (Fig. 1) .
Statistically significant attenuation of thermal hyperalgesia, measured as increased PWL compared to baseline (BL) in the ipsilateral hindpaw, was detected at each day of testing for TTX (8 g/kg, SC) and morphine (5 mg/kg, SC) ( Fig. 2A) . On the first day of drug treatment (Day 3 post-thermal injury) the effect of TTX was not significant until 120 min post treatment, while on the following days TTX had a significant attenuation at both 60 and 120 min. Interestingly, a statistically significant effect of morphine for attenuation of thermal hyperalgesia at the 120 min time point was only observed at days 3 and 7, and at each day at this time point the effect of morphine was less than for TTX. The PWL for TTX and morphine for the 120 min time point was statistically significantly different for days 4, 6 and 7 ( Fig. 2A, brackets) . We note that the BL measurements taken on days 4-7 can also be considered 24 h post treatment measurements for the previous day's treatments. We observed no significant effects of either drug on BL values at any time point, which is expected for morphine. This indicates that like morphine, all of the analgesic effects of TTX are short lived with this dosing regimen in this model. TTX attenuated mechanical allodynia to a statistically significant degree, as measured by grams force to withdrawal, at 60 min post treatment, at days 3-5, and at 120 min post treatment at days 5 and 7 (Fig. 2B) . Morphine attenuated mechanical allodynia at 60 min post treatment on all days, and at 120 min post treatment on days 5-7. For both drugs, the attenuating effects on mechanical allodynia were less robust than on thermal hyperalgesia.
To assess whether central mechanisms are associated with drug effects on behavioral responses, measurements were taken on the contralateral (unburned) paw for both for thermal hyperalgesia and mechanical allodynia (Supplementary Fig. 1 ). Effects of both drugs on contralateral responses were far less that for the ipsilateral hindpaw. However some statistically significant increases in PWL were observed for each drug the 60 min post treatment ( Supplementary  Fig. 1A ). An effect on grams force to withdrawal was only observed for morphine at 120 min post treatment on day 4 ( Supplementary  Fig. 1B) .
Supplementary material related to this article found, in the online version, at http://dx.doi.org/10.1016/j.neulet.2015.09.031.
Finally, to assess potential long-term effects of TTX treatment on pain behaviors, testing was carried out for the same rats at days 10, 14 and 16 post thermal injury, in the absence of drug treatment. There were no statistically significant differences for the rats previously treated with TTX or morphine when compared to vehicle controls at any time point, for either thermal hyperalgesia or mechanical allodynia (Fig. 3) .
Discussion
TTX has been utilized extensively as a tool to study the molecular, biochemical, and pharmacological properties of the 9 Na + channel isoforms Na v 1.1-Na v 1.9 [3] . Among these, six are sensitive to nanomolar concentrations of TTX. They are expressed in the CNS (Na v 1.2), in skeletal muscle (Na v 1.4), in both the CNS and PNS (Na v 1.1, Na v 1.3, and Na v 1.6), and in the PNS including sympathetic neurons (Na v 1.7) [7] . The cardiac muscle specific Na v 1.5, as well as Na v 1.8 and Na v 1.9, which are both expressed in DRG neurons, are not sensitive to TTX [25] . The insensitivity of Na v 1.5 to TTX reduces the likelihood of adverse cardiac effects and TTX has not shown any negative effects in human clinical trials [10, 11] . Interestingly Na v 1.7 has been shown to contribute to the hyperexcitability of sensory neurons [6] , and more recently investigators used spatially controlled Na v 1.7 knock-out mouse models to show that this channel selectively contributes to neuropathic pain in peripheral sympathetic neurons [19] and to burn-induced hypersensitivity, but not mechanical allodynia, in sensory neurons [24] . Accordingly, we set out to test the hypothesis that TTX could provide analgesia for burn wounds by utilizing a characterized rat full thickness thermal injury pain model where we measured the effect of systemic TTX administration on both thermal hyperalgesia and mechanical allodynia. We provide evidence from behavioral assays that TTX is analgesic for thermal injury pain, has a rapid onset and can have a greater analgesic effect than morphine, particularly with repeated use over a 5 day time course. TTX had a more robust suppression of burn-induced thermal hyperalgesia than of mechanical allodynia, which is consistent with the results obtained using a Na v 1.7 knock-out mouse model in which sensory neurons lack expression [24] . However, we note that those investigators found no effect of Na v 1.7 loss on the development of mechanical allodynia after burn injury. This would imply that the modest effect that we observe on suppression of mechanical allodynia is either due to inhibition of other TTX-sensitive Na+ channels present in the PNS (Na v 1.1, Na v 1.3, and Na v 1.6), or due to inhibition of Na v 1.7 in other parts of the PNS besides the peripheral nociceptors. Indeed, Minett et al. showed that when Na v 1.7 was knocked out in all sensory neurons, there was complete loss of all mechanical, inflammatory and heat pain responses [19] .
Data collected from the contralateral paw indicated that TTX at the concentration used (8 g/kg), even when systemically administered, had minimal observable effect on response behavior. This indicates that TTX did not affect the central nervous system in regards to consciousness or muscle control. This is supported by previous results showing that TTX did not reduce rotarod latency, which is another measure of potential effects of a drug on the CNS and/or muscle function, in a mouse paclitaxel-induced neuropathic pain model [20] . In addition, it has long been accepted that the majority of TTX effects can be explained through peripheral mechanism, and that it does not cross the blood-brain barrier to significant degree [8] . Taken together, along with our data, this strongly suggests that TTX can provide analgesia through peripheral mechanisms of action for cutaneous thermal injury, without CNS and/or muscle function impairment.
Administration of TTX blocked thermal hyperalgesia at each day of treatment, and by the 2nd day of drug administration (day 4 post thermal injury), its effect exceeded that of morphine (Fig. 2 , left column). This difference was apparent at 60 min post-drug treatment, however it was statistically significant at 120 min post-drug treatment for days 4, 6, and 7 ( Fig. 2A, bracketed asterisks) . It is likely that repeated morphine injection produced analgesic tolerance in our model, as previously reported in multiple opioid studies [22] . Importantly, a tolerance effect, manifested as a reduced effect of a treatment on the PWL or grams force to withdrawal, was not observed for TTX. Another concern related to opioid use is the development of opioid-induced hyperalgesia, which is the paradoxical increase in sensitivity to painful stimuli experienced after repeated administration of opioids [4] . Although our experiments were not designed to detect this phenomenon, an increase in sensitivity to injection was qualitatively observed for the morphine treated, but not TTX treated rats upon needle stick at time of drug administration. This sensitivity, characterized by tensing of muscle, flinching and vocalization at the time of needle stick, was apparent by the third or fourth day of injection for only the morphine treated rats and was most pronounced by the 5th injection.
Finally, in addition to the behavioral testing on days of drug administration, both thermal hyperalgesia and mechanical allodynia were tested at days 10, 14, and 16 post thermal injury, without TTX administration. We observed levels of thermal hyperalgesia and mechanical allodynia that are typical for untreated rats in the FTTI model at those time points; suggesting that there were no long term effects or likely functional changes to TTX-sensitive sodium channels due to prior daily injections of TTX.
The clinical program for the treatment of cancer related pain using TTX has advanced past completion of a phase III trial in Canada and Phase III trials for chemotherapy induced neuropathic pain are planned in the United States. Through the entire clinical development program for the product, TTX has been administered to more than 500 patients. The initial phase II study was a multi-dose efficacy study (ranging from 15 to 90 g TTX daily), followed by a randomized, double blind, placebo controlled trial using 30 g subcutaneous injections b.i.d. for 4 days. The trials showed a reduction in pain intensity and there was pain relief for up to two weeks or longer post TTX administration, with only mild motor function and mild sensory complications reported [10, 11] . No loss of analgesic effect, signs of addiction, cumulative toxicity, or development of tolerance has been reported [12] . Future clinical trials will explore other potential applications of TTX. To date, there have been no clinical trials examining the analgesic effects of TTX for burn-related pain. Given its efficacy in multiple animal pain models, including our findings in a burn pain model, and the promise shown in clinical trials for cancer-related pain and chemotherapy induced neuropathic pain, such trials in a burn indication are warranted.
Conclusion
In the present study we show that TTX is an effective analgesic in a rat burn wound pain model, and this supports our proposal to develop TTX as a treatment for burn wound pain. These results indicate that TTX can produce analgesia that is as effective as, or superior to morphine, without producing many of the deleterious opioid-related side-effects, such as tolerance, hyperalgesia, or motor function impairment. Our long term goal is to improve the pain care of US military combat casualties, in particular those suffering from severe burn wounds. Part of that goal has been to develop analgesics that can either replace, or reduce the need for opioids such as morphine and fentanyl, which are currently the mainstay analgesics for burn pain [2, 5] . We suggest that TTX could serve as an effective substitute for opioids, both on the battlefield, as well as at later stages of burn injury care.
